Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 194

The DOI matches its Crossref record.

Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.

Keilholz, U, Conradt, C, Legha, S S, Khayat, D, Scheibenbogen, C, Thatcher, N, Goey, S H, Gore, M, Dorval, T, Hancock, B, Punt, C J, Dummer, R, Avril, M F, Bröcker, E B, Benhammouda, A, Eggermont, A M, Pritsch, M · 1998 · Journal of Clinical Oncology

Abstract

PURPOSE: In patients with stage IV melanoma, durable responses have been reported with treatment regimens that involve high-dose interleukin-2 (IL-2). We analyze long-term results of 631 melanoma patients from 12 institutions who had received IL-2 alone, in combination with interferon alfa 2a or 2b (IFNalpha), or with cytotoxic drugs. METHODS: Case records that contained pretreatment parameters, response data, and updated survival information were collected. After univariate analysis, the multivariate evaluation of the impact of pretreatment parameters on response and survival was performed by logistic regression and Cox's regression, respectively. RESULTS: Patients were divided into four groups according to treatment: IL-2 alone (n=117), IL-2 and chemotherapy (n=49), IL-2 and IFNalpha (n=153), and IL-2, chemotherapy, and IFNalpha (n=312). The median survival of all patients was 10.5 months and the 2- and 5-year survival rates were 19.9% and 10.4%, respectively. Independent prognostic factors for response and survival were entirely different, treatment group being the only significant factor for response, and serum lactate dehydrogenase (LDH), metastatic site, and performance predicting survival. The addition of IFNalpha to IL-2 was associated with prolonged survival, but the effect of additional chemotherapy was less obvious. CONCLUSION: Serum LDH, metastatic site, and performance status are useful stratification factors for randomized trials in metastatic melanoma. The improved long-term survival rates observed in melanoma patients treated with IL-2/IFNalpha-containing regimens are notable in contrast to the reported 5-year survival rates of 2% to 6% achieved with chemotherapy, but because selection bias cannot be ruled out, the impact of IL-2, as well as all other components of the treatment regimens, on survival needs to be confirmed in prospective randomized trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.1998.16.9.2921

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 194

Metadata

Authors
Keilholz, U., Conradt, C., Legha, S. S., Khayat, D., Scheibenbogen, C., Thatcher, N., Goey, S. H., Gore, M., Dorval, T., Hancock, B., Punt, C. J., Dummer, R., Avril, M. F., Bröcker, E. B., Benhammouda, A., Eggermont, A. M., & Pritsch, M.
Venue
Journal of Clinical Oncology
Published
1998-09
Volume
16
Issue
9
Pages
2921-2929
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W1831317193
Cited by
194
References
0
FWCI
5.91
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. https://app.cochat.ai/papers/10.1200/jco.1998.16.9.2921
The paper
Keilholz, U., Conradt, C., Legha, S. S., Khayat, D., Scheibenbogen, C., Thatcher, N., Goey, S. H., Gore, M., Dorval, T., Hancock, B., Punt, C. J., Dummer, R., Avril, M. F., Bröcker, E. B., Benhammouda, A., Eggermont, A. M., & Pritsch, M. (1998). Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1998.16.9.2921

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.